Pazopanib, an oral multi-targeted tyrosine kinase inhibitor with activity against VEGFR, PDGFR, and KIT, which has been approved as the first molecular targeting drug for advanced STS, also demonstrated an insufficient response in patients with LPS subtypes [10, 11]. The gene discussed is PDGFRB; the disease is telomere syndrome.